Reaction
Product Blister Packaging Issue reporting signals
As of the last recalculation, Product Blister Packaging Issue appears in 1,015 FAERS reports alongside 15 co-occurring drug terms. The strongest observed disproportionality signal is LOPERAMIDE HYDROCHLORIDE AND DIMETHICONE (PRR 72.4).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Loperamide Hydrochloride And Dimethicone | 102 | 72.4 | 72.6 |
| Suvorexant | 28 | 45.5 | 45.6 |
| Loperamide Hydrochloride | 74 | 36.5 | 36.6 |
| Asenapine Maleate | 14 | 33.6 | 33.6 |
| Ixazomib | 29 | 21.2 | 21.3 |
| Nirmatrelvir And Ritonavir | 39 | 15.3 | 15.3 |
| Valsartan And Hydrochlorothiazide | 10 | 15.2 | 15.3 |
| Emtricitabine And Tenofovir Alafenamide | 7 | 12.7 | 12.7 |
| Axicabtagene Ciloleucel | 6 | 12.5 | 12.5 |
| Nilotinib | 17 | 12.0 | 12.0 |
| Fesoterodine Fumarate | 6 | 11.4 | 11.4 |
| Alpelisib | 4 | 9.4 | 9.4 |
| Loratadine And Pseudoephedrine Sulfate | 3 | 7.8 | 7.8 |
| Cenobamate | 3 | 7.4 | 7.4 |
| Selinexor | 3 | 7.1 | 7.1 |